| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Mass Bankers has been a devoted champion and supporter of Massachusetts banks since 1905. Banking has the power to change communities, one person at a time, one business at a time. By supporting our banks, we like to think we can change Massachusetts, too. Were here for banks to be there. Weve spent over a century creating resources, changing policy, and providing a common ground for banks in Massachusetts to be the best they can be. Because all of us can be better. Massachusetts banks provide support, education, and opportunity for the members of their communities. At Mass Bankers, our job is to make sure our member banks are able to do their best work. From providing educational resources to advocating for meaningful change, we make sure that banks in Massachusetts have all the tools they need to support the people around them. We support our member banks through: • Professional Development • Advocacy • Member Services • Community Website http://www.massbankers.org Phone 617-523-7595 Industry Banking Company size 11-50 employees 40 associated members Headquarters Boston, MA
Based in the Pacific Northwest of the United States, SSC North America is a hypercar manufacturer that specializes in limited production vehicles for elite clientele around the world. In 2007, the SSC Ultimate Aero, a high performance hypercar produced by SSC, legitimized the companys standing as a leading player in the worldwide hypercar market by officially becoming the "Worlds Fastest Production Car" as witnessed and recorded by Guinness World Records. The Ultimate Aero achieved an average two-way speed of 256.18 mph, making SSC one of only 26 manufactures in world history to hold this prestigious title. Today, SSC North America is in the late development stages of the next world record breaking hypercar, the Tuatara. With the Ultimate Aeros record setting achievements and the world renowned performance brought by the next generation Tuatara, SSC North America stands firmly as a great American hypercar company, and will continue to lead innovation in the hypercar market.